AM or DEA cytotoxicity. In conclusion, AM activates primarily necrotic pathways, whereas DEA activates both necrotic and apoptotic pathways, and the renin-angiotensin system does not appear to be involved in AM or DEA cytotoxicity in HPL1A cells.
Introduction
Amiodarone (AM), an iodinated benzofuran, is considered to be the most efficacious antidysrhythmic drug currently available (Lafuente-Lafuente et al., 2009 ).
However, chronic treatment with AM is associated with several adverse effects, the one of greatest concern being AM-induced pulmonary toxicity (AIPT), since it can progress to potentially life-threatening pulmonary fibrosis. Recent studies have reported that the incidence of AIPT occurs in 5-13% of patients treated with AM, in a dose-and durationdependent manner (Oyama et al., 2005) . The prognosis of a patient with AIPT is poor, with a 10-23% mortality rate (Oyama et al., 2005; Vrobel et al., 1989 ).
AM and its major pharmacologically active metabolite, desethylamiodarone (DEA), have large apparent volumes of distribution and slow clearances from adipose tissue, liver, lungs and lymph nodes, and therefore accumulate to high concentrations in these tissues (Freedman and Somberg, 1991) . Following chronic therapy, AM can accumulate in lung to >1 mmol/kg wet tissue (Brien et al., 1987) . In addition, DEA has greater cytotoxic potency than AM and can accumulate in lung to up to four times greater levels than does AM (Broekhuysen et al., 1969; Wilson and Lippmann, 1990; Reasor and Kacew, 1996) . Hence, there is compelling evidence that DEA plays a role in AIPT.
The underlying etiology of AIPT is unknown; however, both indirect inflammatory processes and direct toxic effects have been proposed (Reasor and Kacew, 1996) . AM and DEA are directly toxic to bovine arterial endothelial cells, alveolar macrophages, interstitial lung fibroblasts (Martin and Howard, 1985) , human pulmonary arterial endothelial cells (Powis et al., 1990) , bronchial epithelial cells (Colgan et al., 1984) and hepatocytes (Gross et al., 1989) 
. Many mechanisms have been hypothesized
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JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on June 21, 2017 jpet.aspetjournals.org Downloaded from JPET #173120 5 to cause the direct toxicity of AM and DEA, including increased intracellular influx of Ca 2+ (Powis, et al., 1990) , mitochondrial disruption (Bolt et al., 2001 a) , free radical and ROS formation (Pollak, 1999) and up-regulation of the renin-angiotensin system (RAS) (Uhal, et al., 2006) .
Studies have indicated that rat lung epithelial cells and human lung adenocarcinoma cells have an intrinsic RAS, with the ability to generate angiotensin II (Ang II) de novo (Li et al., 2003) . Ang II signaling, mediated via the angiotensin receptors AGTR1 and AGTR2, plays a role in tissue remodelling in fibrosis (Konigshoff et al., 2007) . However, the downstream effects of AGTR1 and AGTR2 activation are quite different. The classic physiological effects of Ang II, including vasoconstriction, aldosterone and vasopressin release, sodium and water retention, and cell proliferation, are mediated by AGTR1, whereas the established role of AGTR2 includes modulation of biological processes involved in development, cell differentiation, tissue repair and apoptosis (Kaschina and Unger, 2003) . Ang II can induce concentration-dependent apoptosis in human lung cancer epithelial cells and in primary type II pneumocytes isolated from adult Wistar rats, an effect which can be abrogated by the nonselective AGTR antagonist saralasin (Wang et al., 1999a) . In addition, treatment with the angiotensin converting enzyme inhibitor captopril can attenuate apoptosis in human lung adenocarcinoma cells and primary rat alveolar epithelial cells treated with AM or DEA (Bargout et al., 2000) , and can inhibit alveolar wall collagen formation in lungs of AM treated rats . Furthermore, a retrospective review of patients taking AM suggests that patients who developed AIPT were administered a lower dose of RAS This article has not been copyedited and formatted. The final version may differ from this version. inhibitor than were those who did not develop AIPT (Nikaido et al. 2008) . Thus, the RAS may play a contributing role in the initiation and/or progression of AIPT.
Surfactant-secreting type II alveolar epithelial cells provide antioxidant defense, local immunomodulation and a stem cell reserve for alveolar epithelial repair, and are critical for normal re-epithelialization and healing without fibrosis of the alveolar surface (Thannickal et al., 2004) . Histological analysis of lung tissue from patients treated with AM demonstrates alveolar interstitial damage including hyperplasia of type II pneumocytes (Brien et al., 1986) . In addition, AM is toxic to epithelial cells in vitro (Bargout et al., 2000) , thereby implicating epithelial injury in the initiation of AIPT. In order to better understand the etiology of AIPT, the present study investigated the cytotoxic pathways activated by AM or DEA individually and whether an intrinsic RAS is linked to AM-or DEA-induced cell death. HPL1A cells, which were established by immortalization from a normal adult lung specimen, were employed because they retain morphological and biochemical features characteristic of normal adult human peripheral lung epithelial cells (Masuda et al., 1997) .
This article has not been copyedited and formatted. The final version may differ from this version. The amount of AM and DEA in cell pellets was measured as described by Bolt et al. (1998) . Briefly, each cell pellet was thawed, and 100 mixture was centrifuged at 16 000 x g for 3 min at room temperature. The supernatants were analyzed quantitatively for AM and DEA by reverse-phase HPLC with UV-visible spectrophotometric detection at 254 nm, with a with-in day precision of 7.00% (Brien et al., 1983; Brien et al., 1987) . The percent conversion of AM to DEA for each treatment condition was calculated. The mean value from three independent experiments was used to calculate the overall percent conversion of AM to DEA for each treatment condition.
The lower limit of quantifiable detection for DEA was 0.20 
Evaluation of Protection Against AM or DEA Cytotoxicity by Captopril
The angiotensin converting enzyme inhibitor captopril was ineffective at 
Discussion
DEA has greater cytotoxic potency than AM and accumulates in tissues to a greater extent than AM following chronic treatment of humans with AM (Broekhuysen et al., 1969; Wilson and Lippmann, 1990) . Given the high toxicity of DEA, and that DEA is a major metabolite of AM, it is possible that many of the initiating processes of AIPT are not due solely to AM, but also to DEA. After chronic therapy, up to millimolar concentrations of AM and DEA can be found in lung, making the concentrations used in the in vitro studies well within the therapeutically relevant range. In addition, patients who develop amiodarone-induced fibrosis are on the same treatment protocols as those patients who achieve millimolar concentrations of AM and DEA.
In vitro studies investigating cell types in isolation are useful for differentiating the effects of a xenobiotic versus its metabolite(s), if metabolism of the xenobiotic does not occur appreciably in the cells of interest. In humans, AM is metabolized to DEA predominantly by cytrochrome P450 enzymes 3A4, 2C8 and 1A1 (Ohyama et al., 2000) , which are expressed primarily in the liver, although evidence exists of mRNA and protein of these enzymes in human lung (Mace et al., 1998; Nishimura et al., 2003) .
In HPL1A cells, less than 2% of AM was converted to DEA over 24 h. The fact that the percent conversion of AM to DEA decreased with increasing AM concentration was likely due to the direct cytotoxicity of AM at the higher concentrations rather than saturation of biotransforming enzymes, since the K M value for cytochrome P450 3A production of DEA in liver microsomes is 0.33 mM (Fabre et al., 1993) , a concentration well above those used in this study. AM is not converted to DEA to an appreciable extent during the incubation times employed, the HPL1A cell culture model can be used to study the effects of AM and DEA independently on lung epithelial cells.
As observed previously in other systems (Bolt et al., 2001a; Broekhuysen et al., 1969; Nicolescu et al., 2008; Wilson and Lippmann, 1990) , DEA proved to be a more potent and rapidly acting cytotoxicant than AM in HPL1A cells. Both agents caused HPL1A cell death predominantly by necrosis. Other studies investigating apoptotic and necrotic pathways induced by AM or DEA in other cell types have also found a concentration-dependent increase in necrosis (Bargout et al., 2000; Yano et al., 2008) .
After AM treatment, we also found a concentration-dependent decrease in apoptosis at 6
and 12 hours, but not at 24 hours as reflected by ann-V staining. The percentage of HPL1A cells that underwent apoptosis, however, was small (1.6 -12.3%). Therefore, necrosis predominates over apoptosis in AM toxicity. Apoptosis and necrosis can occur in a continuum, whereby cells can undergo processes that have the potential to lead to apoptosis, but can ultimately later undergo necrosis, depending on the magnitude of the insult, duration of toxicant exposure, energy requirements, etc. The ann-V staining results suggest that the pronounced cytotoxicity of the higher concentrations of AM resulted in a shift in the apoptotic-necrotic continuum, resulting in virtually all cells dying via necrosis. This finding in the non-transformed HPL1A human lung epitheliumderived cells contrasts with the results from A549 human lung adenocarcinoma cells and rat alveolar epithelial cells (Bargout et al., 2000; Yano et al., 2008) , in which AM caused a concentration-dependent increase in apoptosis. However, in both the previous studies and the present study, both apoptosis and necrosis were observed following exposure to AM or DEA, and necrosis predominated. Unlike AM, DEA induced apoptosis in HPL1A cells, although the lowest concentration at which apoptosis was detected differed depending on the assay used ( Figures 2C and 4F ). This difference can be attributed to the different end points assayed, in that ann-V staining indicates phosphatidylserine externalization, an early event in apoptosis relative to DNA fragmentation, which is detected by TUNEL staining (JetzekZader et al., 2007) . This is consistent with the fact that the percentage of TUNEL positive control cells was lower than the percentage of ann-V positive control cells ( Figure 2C and Figure 4F ). If a longer incubation time were to be tested, the percentage of control cells containing fragmented DNA would be expected to increase. The initial induction of ann-V positive cells was not sustained at higher concentrations of DEA, which is consistent with the marked toxicity associated with 5 μ M DEA, a concentration that caused an even greater proportion of the cells to undergo necrosis. These DEA results are also consistent with those of other studies (Bargout et al.,2000; Waldhauser et al., 2006) , in which DEA increased both apoptosis and necrosis.
Taken together, the results from the present study suggest that the cytotoxic pathways induced by AM and DEA differ somewhat in HPL1A cells. AM induces necrotic cell death, while DEA induces both necrotic and apoptotic cell death despite being the more potent cytotoxicant. DEA caused an increase in PI positive cells prior to an increase in ann-V positive cells. Since PI enters cells when the plasma membrane becomes permeable during necrosis, this suggests that DEA-induced necrosis occurred prior to apoptosis and that the two cell death processes are occurring simultaneously in different cell populations, which has been proposed previously (Leist et al., 1997; Yano et al., 2008) . This concept is best illustrated in Figure 3 , wherein four cell populations This article has not been copyedited and formatted. The final version may differ from this version. (Leist et al., 1997) .
A549 cells possess an intrinsic RAS with the ability to generate Ang II de novo (Wang et al., 1999b within the range found in lungs of patients treated clinically with AM (Brien et al., 1987; Plomp et al., 1984) . Therefore, a RAS-independent mechanism appears to be responsible for AM and DEA cytotoxicity in non-transformed human lung epithelial cells, but our findings do not preclude the involvement of Ang II and the RAS in the progression of
AIPT in vivo.
This article has not been copyedited and formatted. The final version may differ from this version. 
